The Economic Burden of Migraine to Society
- 147 Downloads
The financial burden of migraine on society comprises direct costs, associated with medical care, and indirect costs, caused by absence from work and reduced productivity.
Recent studies have revealed that direct costs are generally relatively low in Europe, but are much higher in North America, probably because of increased use of emergency room and specialist consultations for the treatment of migraine. Most individuals who experience migraine headaches take medication (over-thecounter, prescription-only or a combination of both) for their condition; in Europe and North America, most patients who experience migraines have consulted a physician at some time because of their condition.
In general, the estimated indirect costs of migraine are substantial and are much higher than estimates of direct costs. On average, work losses related to reduced productivity are higher than those related to work absence. These data demonstrate the importance of the societal impact of migraine and illustrate the need for improved strategies to target migraine treatment.
KeywordsMigraine Adis International Limited Indirect Cost Direct Cost Migraine Attack
Unable to display preview. Download preview PDF.
- 1.Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 19–28Google Scholar
- 3.Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Manage Care 1996; 2: 139–43Google Scholar
- 6.Stang PE, Osterhaus JT, Celentano DD, et al. Migraine: problems of healthcare. Neurology 1994; 44 Suppl. 4: S47–55Google Scholar
- 12.Micieli G. Suffering in silence. In: Edmeads J, editor. Migraine: a brighter future. Worthing: Cambridge Medical Publications, 1993: 1–7Google Scholar
- 13.Parry TG. The prevalence and costs of migraine in Australia. Kensington: University of New South Wales, 1992. Centre for Applied Economic Research (CAER) working paper no.: 1992/1Google Scholar
- 14.Björk S, Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991. Working paper no.: 8Google Scholar
- 15.Blau JN, Drummond MF. Migraine. London: Office of Health Economics, 1991Google Scholar
- 16.Bloomberg Financial Markets. Electronic database. New York: LP Bloomberg, 1998Google Scholar
- 17.International Monetary Fund (IMF). International financial statistics. Vol. 11 (1). Washington, DC: IMF, 1998Google Scholar
- 20.Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15Google Scholar
- 21.Láinez JM, Titus F, Cobaleda S, et al. Socioeconomic impact of migraine [abstract]. Funct Neurol 1996; 11: 133Google Scholar
- 28.Göbel H, Petersen—Braun M. Why patients with primary headaches do not consult a doctor. In: Olesen J, editor. Headache classification and epidemiology. New York: Raven Press Ltd, 1994: 267–72Google Scholar
- 31.Sawyer J, Edmeads J, Lipton RB, et al. Clinical utility of a new instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire [abstract]. Neurology 1998; 50 Suppl. 4: A433–4Google Scholar